CUDC 305

Drug Profile

CUDC 305

Alternative Names: CU-0305; CUDC-305; DEBIO 0932; Debio-0932

Latest Information Update: 06 Oct 2015

Price : $50

At a glance

  • Originator Curis
  • Developer Curis; Debiopharm
  • Class 2 ring heterocyclic compounds; Antineoplastics; Benzodioxoles; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Cancer
  • Discontinued Lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 19 Jun 2015 CUDC 305 is available for licensing as of 19 Jun 2015. http://www.curis.com/
  • 11 May 2015 Phase-I clinical trials in Cancer in USA (PO)
  • 01 Feb 2015 Curis re-acquires CUDC 305 from Debiopharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top